C
SPRY icon

Covestor’s ARS Pharmaceuticals SPRY Stock Holding History

Covestor’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
46
+39
+557% +$335 ﹤0.01% 2817
2026
Q1 		$0 Hold
7
– – ﹤0.01% 2734
2025
Q4 		$0 Sell
7
-1
-13% -$10 ﹤0.01% 2707
2025
Q3 		$0 Hold
8
– – ﹤0.01% 2736
2025
Q2 		$0 Hold
8
– – ﹤0.01% 2722
2025
Q1 		$0 Hold
8
– – ﹤0.01% 2692
2024
Q4 		$0 Sell
8
-3
-27% -$42 ﹤0.01% 2701
2024
Q3 		$0 Sell
11
-1
-8% -$12 ﹤0.01% 2724
2024
Q2 		$0 Buy
+12
New +$106 ﹤0.01% 2717

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Covestor's SPRY Position: Q2 2026 in Review

Covestor increased its ARS Pharmaceuticals (SPRY) stake by 557% in Q2 2026, buying an estimated $335 and bringing the position to 46 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2817.

Covestor first reported a position in SPRY in Q2 2024 and has held it in 9 quarters since. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Covestor held 46 shares of ARS Pharmaceuticals worth $0 as of Q2 2026.
  • Covestor bought 39 ARS Pharmaceuticals shares in Q2 2026, an estimated $335.
  • ARS Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2817 holding.
  • Covestor first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.